The UK and US have agreed to a important trade agreement that will preserve no duties on UK drug exports entering the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise spending on drugs through the public health system. This pledge secures that duties on these crucial products will remain at zero for a duration of 36 months.
This agreement is in response to previous threats to hike duties on branded pharmaceutical products, with figures floated up to double the cost.
"This agreement between the UK strengthens the international landscape for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. drug exports," an announcement declared.
Trade Significance
Medicines represent one of the Britain's biggest exports to the America, which is clearly the largest buyer for large UK drugmakers.
Trade data show that in the year leading up to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards work, boosts capital expenditure and facilitates the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, refunds topped 20%.
Industry Background
This agreement takes place against a protracted tension between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were exacerbated by assertions that American consumers were paying significantly more for the same drugs than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been directed toward US facilities.
One official publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the previous ten-year period.
